Vanta Bioscience Ltd.

As of March 31, 2026, Vanta Bioscience Ltd. carries a market capitalization of 107.75M, placing it among publicly traded companies globally. Its enterprise value stands at 487.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Vanta Bioscience Ltd. has 7.11M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Vanta Bioscience Ltd. maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 16, 2026, Vanta Bioscience Ltd.'s stock has declined approximately 20.22% over the past 52 weeks. The 50-day moving average sits at 21.21, while the 200-day moving average is 22.78.

As of March 31, 2026, Vanta Bioscience Ltd. holds 1.35M in cash and equivalents against 380.78M in total debt, resulting in a net debt position of 379.43M. Total book value stands at 211.76M, with working capital of 23.11M providing operational flexibility.